TrialJournal for immunotherapy of cancer2023

Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B).

Michael B Atkins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.